What the Study Found (In Plain English)
Published in Molecular neurobiology (2025), this randomized controlled trial evaluating 19 human participants investigated: Major depressive disorder (MDD) remains a leading cause of disability worldwide, and while selective serotonin reuptake inhibitors (SSRIs) are standard treatments, they have limited efficacy and adverse effects. Key clinical takeaway: THC demonstrates antidepressant potential through anti-inflammatory and neuroprotective mechanisms, supporting its use as a safe augmentation strategy in MDD treatment. Further trials are warranted to validate its clinical efficacy and molecular targets.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Molecular neurobiology, 2025-12-23; N = 19; Rigor 82/100): THC demonstrates antidepressant potential through anti-inflammatory and neuroprotective mechanisms, supporting its use as a safe augmentation strategy in MDD treatment. Further trials are warranted to validate its clinical efficacy and molecular targets.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.